stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Revenue growth
Arrowhead Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 June 2026 was 16.1%, down 23242.0 percentage points from fiscal 2025 (23,258.2%). Over the past ten years it has ranged from −98.5% (fiscal 2024) to 23,258.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 23,258.2% | 23,356.67 |
| FY2024 | −98.5% | (97.49) |
| FY2023 | −1.03% | (76.92) |
| FY2022 | 75.9% | 18.73 |
| FY2021 | 57.2% | 105.03 |
| FY2020 | −47.9% | (993.55) |
| FY2019 | 945.7% | 994.28 |
| FY2018 | −48.6% | (19,789.22) |
| FY2017 | 19,740.6% | 19,799.18 |
| FY2016 | −58.6% | (176.85) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 171.0% | 257.43 |
| Mar 2026 | −86.4% | (10,547.73) |
| Dec 2025 | 10,461.3% | 3,338.79 |
| Sep 2025 | 7,122.5% | 7,050.03 |
| 39 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. compare | 92.8% |
| CAI Caris Life Sciences,�Inc. compare | 68.8% |
| PTGX Protagonist Therapeutics, Inc. compare | 34.8% |
| CORT Corcept Therapeutics Incorporated compare | 30.0% |
| CYTK Cytokinetics, Incorporated compare | 29.9% |
| KRYS Krystal Biotech, Inc. compare | 26.0% |
| TWST Twist Bioscience Corporation compare | 19.2% |
| ARWR Arrowhead Pharmaceuticals, Inc. | 16.1% |
| SYRE Spyre Therapeutics, Inc. compare | −81.8% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement